(Q52081789)

21 April 2018

title

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. (English)

1 reference

21 April 2018

1 reference

1 reference

Burgess DS

1

1 reference

21 April 2018

Hastings RW

series ordinal

2

1 reference

21 April 2018

Hardin TC

series ordinal

3

1 reference

21 April 2018

publication date

1 January 2000

1 reference

21 April 2018

published in

Clinical Therapeutics

1 reference

21 April 2018

volume

22

1 reference

21 April 2018

issue

1

1 reference

21 April 2018

page(s)

66-75

1 reference

21 April 2018

Continuous infusion of beta-lactam antibiotics

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Treatment of gram-negative bacillary septicemia with cefoperazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Serum bactericidal activity after administration of four cephalosporins in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987978-3

7 January 2021

10.1016/S0149-2918(00)87978-3

Identifiers

DOI

1 reference

21 April 2018

1 reference

21 April 2018